Samsung Biologics clears takeover threshold with 87.88% of PolyPeptide tendered
The tender result gives the Korean manufacturer control of the Swiss peptide contract developer and maker.
TR
By Tom Reyes · Markets Editor
Oct 13 02:14 ETSource: Korea Biomedical Review
The wire
- 01Samsung Biologics said 87.88% of PolyPeptide shares were tendered, clearing the threshold for its takeover of the peptide-focused CDMO.
- 02PolyPeptide is a significant contract supplier of peptide APIs, so ownership change matters to companies sourcing peptide manufacturing capacity.
- 03Closing terms and any remaining regulatory or squeeze-out steps were not detailed in the report.
From the source
Read at koreabiomed.comSamsung Biologics clears takeover threshold as 87.88% of PolyPeptide shares tendered
